Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
-
Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
-
Vantage Drilling International Ltd. – Announcement of Contract Termination
-
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
-
FreightTracker Receives Strategic Growth Investment from Arcadea Group
-
Keo World Triumphs at the Le Fonti Awards 2025 with Its Revolutionary B2B Credit Solution: The Fintech Transforming Finance
-
Important Notice to Long-Term Shareholders of Baxter International Inc. (BAX): Grabar Law Office Investigates Claims on Your Behalf
-
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
-
Nexzen Extracts — The Best THCA Brand Launches Spooky Halloween Sale with Up to 45% Off Sitewide
-
Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025
-
HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet
-
Rockcliffe Labs Launches Canada’s First Venture-Building Platform for Biotechnology and Life Sciences with Mission to Create 100 Companies
-
iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
-
Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
-
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the
-
VT3989, Vivace Therapeutics' Best-in-Class, Hippo Pathway-Targeting Therapy, Demonstrates Promising Antitumor Activity in Refractory Mesothelioma
-
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Amdark Limited Expands Global Reach in Fighting Crypto and Investment Scams Across Canada, UK, and USA
-
Global Times: Over 400 senior guests from over 30 countries, regions to attend conference of Financial Street Forum 2025 in Beijing: organizers
-
/C O R R E C T I O N -- Spinogenix/
-
United Imaging Marks Five Years Since the Opening of its Global Showroom In North America with a Record Number of U.S. Customer Visits
-
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
-
Max Stock Limited releases an immediate report on holdings of interested parties and senior officers as of September 30, 2025
-
HDAI to announce AI tools that drive quality outcomes at HLTH 2025
-
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
-
PayrollOrg's Educational Institutions Payroll Conference to Equip Higher Ed Payroll Professionals with Essential Compliance and Technology Insights
-
Innovation Rooted in Listening: Relaxure Custom Pergolas Bring Smart Comfort to Every Home
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at E
-
Startuprad.io Launches Startup AI Concierge for Europe's Startup Ecosystem
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
What 50 Failed Startups Teach About Modern Management
-
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
-
Historical Adventure Series ‘Adventures in Time' Inspires Young Readers to Explore the Past
-
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
-
Mutuum Finance (MUTM) Progresses Toward Q4 2025 Testnet Launch With $17.6 Million Raised
-
Kuardin Sets a New Benchmark for Real-World Integration in Digital Commerce
-
Cardano Price Prediction Revised Downwards as All Eyes Turn to Digitap’s ($TAP) Path to $20
-
ChillPlay Games announces major overhaul of “Over Hit: Hero Fight” surpassing 50,000 downloads and introducing AI Node powered by Claude AI and MCP
-
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative brea
-
World Winter Sports Expo 2025 Officially Opened
-
FBS AI Assistant Helps Traders Skip Market Noise and Focus on Strategy
-
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
-
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
-
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
-
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
-
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
-
Falcon Finance Publishes Strategy Allocation Breakdown for Yield Generation Transparency
-
The 2025 Chery International User Summit Opens a New Chapter as AiMOGA Robotics Unveils Its Global Brand Strategy
